GlassScriptPhysician profile
Arianna Ryan
NPI 1275930950
$5,215.77
in general payments reported to CMS, 2019-2025
20 companies · $1,566 in 2025
The $1,566 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $107 · 2022: $374 · 2023: $1,314 · 2024: $1,855 · 2025: $1,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,734.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $978.39 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $971.78 | 2023-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $676.55 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $497.64 | 2022-2025 | |
| Abbott Laboratories | $443.28 | 2023 | Freestyle Libre 3 |
| Nevro Corp. | $269.62 | 2024 | Senza |
| Astrazeneca Pharmaceuticals LP | $247.65 | 2021-2025 | Farxiga, Airsupra |
| Dexcom, INC. | $238.71 | 2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Pfizer INC. | $170.09 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $158.96 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.57 | 2025 | Xifaxan |
| Inspire Medical Systems, INC. | $139.34 | 2024-2025 | Inspire |
| Exact Sciences Corporation | $73.40 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $60.86 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.69 | 2024 | Elaprase |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $26.48 | 2024 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.62 | 2025 | Jardiance |
| Optinose US, INC. | $20.45 | 2022 | |
| Genentech USA, INC. | $15.69 | 2022 | |
| Si-Bone, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arianna Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.